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Objectives The objective of the present study was to determine bacterial etiology and susceptibility in urinary
tract infections. The study was designed as a retrospective study of urine samples from patients both inside and
outside hospitals and nursing homes that were received at our laboratory between 1 January 1997 and
31 October 1999. The Telemark Biomedical Center receives all the medical microbiology specimens from
hospitals, nursing homes and general practitioners in the County of Telemark (165 000 inhabitants), Norway.
All urines fulfilling the criteria for significant bacteriuria [10 000 colony-forming units/mL urine] were
included in the study.
Methods Bacterial susceptibility testing was performed using breakpoint methodology. During the study
period, we received 52 350 urine samples, of which 28 066 (53.6%) fulfilled the criteria for significant
bacteriuria (pure growth of 10 000 CFU/mL urine).
Results Escherichia coli was the most predominant bacterium in the urine from both inpatients (56.7%) and
outpatients (68.3%). Coagulase-negative staphylococci and enterococci occurred significantly more often
(P< 0.001) in urine samples from inpatients (12.5% and 7.9%) than in urine samples from outpatients (7.5%
and 4.7%). Escherichia coli from both outpatients and hospitalised patients was highly susceptible (>93%) to
cefalothin, mecillinam and nitrofurantoin, and more than 75% of E. coli isolates were also sensitive to
ampicillin. Overall, the susceptibility to nitrofurantoin in bacteria from outpatients was 90% and from
hospitalised patients was 85%. The corresponding figures for cefalothin were 92% and 90%, and for
trimethoprim were 81% and 76%, respectively.
Conclusions Bacteria causing urinary tract infections in Norway are less resistant to antibacterial medication
than in other western countries and the reason for this may be the low consumption of antibacterials by the
Norwegian population. During the period from1990 to 1999 the mean total annual consumption of
antibacterial drugs in Norway was 15.3 defined daily doses per 1000 inhabitants per year.
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INTRODUCTION
Urinary tract infections (UTI) are amongst the most common
infections and account for a large proportion of antibacterial
drug consumption. UTI therefore have large socio-economic
impacts [1] and may contribute to the emergence of bacterial
resistance [2]. To optimise the use of empiric antibacterial
therapy for UTI, physicians should know the etiology of
UTI and the susceptibility patterns of UTI pathogens in their
population. The local medical microbiology laboratories should
monitor the microbial epidemiology of UTI so that any change
in bacterial etiology or susceptibility is detected and updated
recommendations for UTI treatment can be given.
Previous studies have shown that Escherichia coli is the pre-
dominant cause of UTI both in and outside hospitals, and that
the etiology of nosocomial UTI is characterised by a higher
prevalence of enterococci and coagulase-negative staphylococci
[3–8]. Recent studies in North America and western Europe
demonstrated increasing resistance in UTI E. coli to ampicillin,
trimethoprim and sulfonamides [6, 8–11]. In previous studies
from Norway, Kristiansen [3] and Vorland et al. [4] found that E.
coli was the predominant pathogen in UTI both in and outside
hospitals. During the period 1973–80, the resistance of UTI
E. coli to sulfonamides increased in north Norway in step with
an increase in sulfonamide consumption [12].
The aim of the present study was to determine the local
microbial etiology of UTI in and outside hospitals and to
determine the microbial susceptibility to the most commonly
used antimicrobials.
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MATERIALS AND METHODS
All urinary specimens with significant bacteriuria [13] culture
of bacteria 104 colony-forming units (CFU)/mL urine pro-
cessed in our laboratory during the period 1 January 1997 to 30
November 1999 were included in the study (Table 1). Informa-
tion on the physician/hospital and the laboratory results for all
specimens that we process are registered on our laboratory
computer system (Miclis AS, Lillehammer, Norway). Growth
on dip-slides (40% of urine samples) was quantified according to
the manufacturer’s specification. Colonies were picked and
plated on to blood-agar and CLED medium and incubated
overnight at 37 8C. Fresh urine samples (1%) were quantita-
tively plated within 4 h of receipt, and fresh urines with addition
of boric acid (59%) within 24 h, on blood agar and CLED
medium and incubated at 37 8C overnight. The growth was
quantified and bacteria were identified according to standard
procedures [14]. Susceptibility testing was performed using an
automatic multipoint inoculator system (MAST, Merseyside,
UK). Resistance breakpoints were used according to the
Norwegian Working Group on Antibiotics [15]. The following
breakpoints were used: ampicillin 32 mg/L, cefalothin 16 mg/L,
nitrofurantoin 32 mg/L, sulfonamides 128 mg/L and trimetho-
prim 8 mg/L. Enterococci were not tested against mecillinam,
cefalothin and sulfonamide. Coagulase-negative staphylococci
were not tested against ampicillin and mecillinam. In Norway,
quinolones are not recommended for treatment of UTI and
were not tested. The material was divided into two groups. One
group comprised urine samples from patients in hospitals or
institutions for the elderly (inpatients), and in the second group
were samples from patients outside hospitals and institutions
(outpatients). The material was not stratified according to sex,
age, or clinical diagnosis.
Information on consumption of antibacterial drugs
Information on the consumption of antibacterial medication in
Norway is published annually by The Norwegian Medicinal
Depot [16].
Statistical analysis
The data were imported from our laboratory management
program (Miclis A/S, Lillehammer, Norway) and analysed in
a database program (DBASE IIIþ, Ashton-Tate, California,
USA). The statistical analyses [17] were performed by Mericon
A/S, Skien, Norway. Pearson w2 tests are used to test for
homogeneity or independence between row and column vari-
ables, Mantel–Haenzel w2 tests were used to detect linear
association and Cochran–Mantel–Haenzel statistics were used
to do stratified analysis of the row and column variables
adjusting for a third variable (year or institution/not institution).
RESULTS
Urine samples
During the period from 1 January 1997 until 30 October 1999
we analysed 52 350 urine samples, of which 28 066 had sig-
nificant bacteriuria (defined as pure growth of 10 000 CFU/
mL urine). Of these, 5352 urine samples (19.1%) were from
inpatients and 22 714 (80.9%) were from outpatients.
Bacteria
Escherichia coli was the predominant pathogen in urine samples
of both inpatients and outpatients (Table 1), but occurred
Table1 Bacterial etiology in urines from inpatients and outpatients with urinary tract infection
Inpatients Outpatients
Bacterium Number % Number %
E. coli 3035 56.7 15506 68.3
Klebsiella sp. 387 7.2 1364 6.0
Proteus sp. 423 7.9 998 4.4
Enterobacter sp. 50 0.9 171 0.6
Citrobacter sp. 13 0.2 33 0.1
Pseudomonas sp. 69 1.3 34 0.1
Enterococci 423 7.9 1073 4.7
Streptococcus agalactiae 41 0.8 349 1.5
Staphylococcus aureus 116 2.2 444 2.0
Staphylococcus saprophyticus 21 0.4 443 2.0
Coagulase-negative staphylococci 670 12.5 1713 7.5
Other bacteria 104 2.0 586 2.8
Total 5352 100.0 22714 100.0
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significantly more frequently (P< 0.001) in urines from out-
patients (68.3%) than from inpatients (56.7%). The proportion
of coagulase-negative staphylococci was higher in inpatients
(12.5%) than in outpatients (7.5%, P< 0.001) as was the
proportion of enterococci (7.9% and 4.7%, P< 0.001).
Bacterial susceptibility
E. coli
Resistance was only slightly more frequent in E. coli from
inpatients than in E. coli from outpatients (Table 2). A significant
difference was seen only for ampicillin; 75.5% of E. coli from
inpatients and 78.4% of E. coli from outpatients were sensitive to
ampicillin (P< 0.001). We observed a decline in the frequency
of E. coli susceptible to ampicillin during the study period. In
outpatients, sensitivity of E. coli to ampicillin decreased from
80.3% in 1997 to 76.7% in 1999 (P< 0.001), and in inpatients
from 76,5% to 74,3% (P< 0.05). The decline in sensitivity to
sulfonamide of E. coli from outpatients (from 78.4% to 72.8%),
trimethoprim (from 84.6% to 80.9%) and TMX (from 88.4% to
84.8%) was also significant (P< 0.001).
Enterococci
The overall sensitivity of enterococci from both inpatients and
outpatients to ampicillin (98.1% and 97.9%, respectively) and to
nitrofurantoin (98.1% and 98.5%, respectively) was high
(Table 2). However, during the study period there was a sig-
nificant decline in sensitivity to ampicillin in enterococci from
outpatients from 98.9% to 95.8%, P< 0.002). On the other
hand, there was a significant increase in sensitivity to trimetho-
prim (from 58.5% to 71.1%, P< 0.001) and TMX (from 59,1%
to 72,2%, P< 0.001) in enterococci from outpatients.
Coagulase-negative staphylococci
Coagulase-negative staphylococci from both in and outpatients
were predominantly susceptible to cefalotin; 97.5% and 98.7%,
respectively (Table 2). During the study, sensitivity to sulfona-
mide decreased from 89.2% to 78.7% (P< 0.008) in urine
samples from inpatients, and from 91.3% to 83.3% (P<
0.001) in urines from outpatients.
Percentage of susceptible isolates
The percentage of susceptible isolates is important for physicians
to know when empiric treatment is started. Of all bacteria from
inpatients, only 60% were sensitive to ampicillin whereas 90%
were sensitive to cephalothin and 85% to nitrofurantoin
(Table 3). Cefalothin also had the highest mean sensitive rate
(92%) for bacteria from outpatients. Nitrofurantoin was effec-
tive against 90% of bacteria from outpatients and ampicillin to
only 66%.
Consumption of antibacterials in Norway
In Norway, drug consumption is carefully monitored and
categorised according to ATC classification [18]. The con-
sumption is given as Defined Daily Doses (DDD) per 1000
inhabitants per day.
The mean annual consumption of penicillins (ATC group
J01C) between 1990 and 1999 was 7.0 ranging from 6.09 (1990)
to 7.45 (1997). For sulfonamides and trimethoprim (ATC
group J01E) the mean annual consumption was 1.8, ranging
from 1.27 (1999) to 2.15 (1990). The mean annual total
consumption of antibacterials (ATC groups J01 and G04AC
Table 2 Sensitivity (% susceptible) of themost frequently isolated bacteria
E. coli Enterococci Coagulase-negative staphylococci
Antibacterials Inpatients Outpatients Inpatients Outpatients Inpatients Outpatients
Ampicillin 75.5 78.4 98.1 97.9 ND ND
Cefalothin 93.8 96.0 ND ND 97.5 98.7
Mecillinam 96.1 97.0 ND ND ND ND
Nitrofurantoin 97.4 97.5 98.1 98.5 98.1 98.5
Sulphonamides 72.9 75.2 ND ND 81.9 87.7
Trimethoprim 79.3 82.7 60.0 60.8 76.3 86.2
Trimethoprim/sulfamethoxazole 84.3 86.3 60.0 61.1 87.9 94.6
ND, not determined.
Table 3 The percentage of susceptible isolates (%) of all bacteria to antimi-
crobials
Antimicrobial Inpatients Outpatients
Ampicillin 60 66
Cefalothin 90 92
Mecillinam 68 77
Nitrofurantoin 85 90
Suphonamides 69 73
Trimethoprim 76 81
Trimethoprim/sulfamethoxazole 82 86
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nitrofurantoin) in the same period was 15.3, ranging from 14.5
(1990) to 16.6 (1993). In 1999 the total consumption of
antibacterials in Norway was 14.7.
DISCUSSION
The present study is a retrospective study using the results of our
routine diagnostic and susceptibility analyses. We are aware that
not all urines from patients with UTI are sent to our laboratory;
many patients with UTI are treated without bacteriological
testing. The exact etiology and susceptibility patterns in the
study population may therefore deviate from what is presented
by us. Differences in identification methods, susceptibility
testing and criteria for defining ‘significant bacteriuria’ may
differ between laboratories and may change over time. Also
national recommendations for break-points and methodology
may differ. These factors will greatly influence the relative
prevalence of different bacteria and their susceptibility patterns,
and will make comparison between different studies difficult
[19]. Because we have used resistance breakpoints in our study,
we might have overestimated the proportion of sensitive strains
in comparison with others who use lower breakpoints. The
number of positive urine samples in our material (53.6%) is
high. The explanations for this is that a high proportion (40%)
of the samples are sent on dip-slides which have been pre-
incubated and only those with suspected significant growth are
sent. We also receive few urines for screening; it is not common
for general practioners and gynecologists to screen pregnant
women for UTI. Finally, we use the Norwegian criteria for
‘significant bacteriuria’. Therefore, growth of two bacteria may
also be catagorised as ‘significant’ if both are present at
104 CFU/mL urine. In these cases it is possible that the urine
samples have become contaminated.
We found that E. coli is the predominant bacterium in urine
smaples from both inpatients and outpatients. This is in accor-
dance with previous studies [5–8]. In a previous study from
Norway, Kristiansen [3] found E. coli in 52.3% of patients in
hospitals and in 81.5% of outpatients. We found that enter-
ococci and coagulase-negative staphylococci caused a signifi-
cantly higher proportion of infections in inpatients (7.9% and
12.5%, respectively) than in outpatients (4.7% and 7.5%). This
finding correlates well with previous studies [6,7]. Enterococci
and coagulase-negative staphylococci are often multi-resistant
and there may be selection for the multi-resistant phenotypes in
hospitals where there is a higher consumption of antibacterial
drugs.
Bacterial etiology and antibacterial susceptibility may show
geographic variation, but may also vary over time within a
population. In a previous study from Norway [3] E. coli caused
81.5% of UTI in outpatients and 52.3% of UTI in inpatients
compared to 68.3% and 56.7%, respectively, in the present
study. Since the 1970s, the predominance of E. coli in urine
samples from outpatients in Norway seems to have been
challenged by enterococci and coagulase-negative staphylo-
cocci; these were found in only 2.3% and 2.1% of samples in
the 1970s, compared to 4.7% and 7.5% in the current sample
set, respectively. A less pronounced change is also seen in
inpatients. This change in frequency may however, be partially
explained by the change in the cut-off for ‘significant bacter-
iuria’ from pure culture. This has changed from 100 000
bacteria/mL urine before 1992 to 10 000 bacteria/mL urine
since then. This change will increase the representation of
slow-growing bacteria like enterococci and coagulase-negative
staphylococci.
Both in inpatients and outpatients, more than 80% of isolates
of E. coli were sensitive to cefalothin, mecillinam, nitrofurantoin
and TMX. Sensitivity of E. coli to ampicillin, trimethoprim and
sulfonamides exceeded 70% in both groups of patients. How-
ever, sensitivity of E. coli to ampicillin declined during the study
period. This may be explained by an increased selective pressure
caused by the steady increase in consumption of penicillins
(ATC group J01C) from 1990 to 1999. Escherichia coli from
outpatients in Norway were more sensitive than E. coli isolated
from outpatients in Canada. Zhanel et al. [10] found resistances
in E. coli isolates of 41.1% to ampicillin, 19.2% to TMX and
14.2% to mecillinam compared to 21.6%, 13.7% and 3%,
respectively, in our study. The E. coli from inpatients were also
more sensitive than E. coli from inpatients in other studies. In a
study of nursing-home residents in the Netherlands, Vromen
et al. [8] reported that only 41% of E. coli were sensitive to
amoxicillin, 85% to nitrofurantoin and 62% to TMX. In a study
of UTI in hospitalised patients in the USA, Jones et al. [7] found
that 57% of E. coli were sensitive to ampicillin and 75% to TMX.
The sensitivity of E. coli to nitrofurantoin (95%) was similar to
that found in our study (97.5%).
Compared with the previous study from Norway [3] from
the 1970s, the mean sensitivity rates have declined for some
antibacterials. There was a decrease in sensitivity to ampicillin
(from 90% to 66%), sulfonamides (from 84% to 73%) and TMX
(from 98% to 86%) in bacteria from outpatients. In contrast, the
percentage of isolates susceptible to nitrofurantoin increased
from 70% to 90%. This increase in sensitivity is parallelled by a
decrease in the consumption of nitrofurantoin from a mean of
2.7 DDD per 1000 inhabitants per day during the 1970s [3] to
0.4 DDD per 1000 inhabitants per day during the 1990s [16]. It
is tempting to assume that the decreased consumption of
nitrofurantoin caused bacterial sensitivity to increase.
In conclusion, the sensitivity of the most prevalent UTI
pathogens seems to be higher in Norway than in other western
countries which may be explained by the low and restricted
consumption of antibacterial drugs in Norway, although this
may also be in part, due to the high breakpoints used in this
study. The sensitivity to nitrofurantoin is high and increasing,
probably because nitrofuranoin has not been widely used for
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treating UTI during the last decade. The time has come to
consider nitrofurantoin as the primary choice for treating UTI.
It will be an important task for medical microbiology labora-
tories to monitor and report any changes in bacterial etiology
and susceptibility so that treatment of UTI can be optimised in
order to reduce the risk of increasing bacterial resistance. It may
be wise to let some antibacterial drugs ‘rest’ for some years until
sensitivity to these drugs has reached an acceptable level.
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